American Association for Cancer Research
Browse
15417786mcr190040-sup-215259_2_supp_5612250_ptr7cm.pdf (2.28 MB)

Supplementary Figure S1 from The Altered Transcriptome and DNA Methylation Profiles of Docetaxel Resistance in Breast Cancer PDX Models

Download (2.28 MB)
journal contribution
posted on 2023-04-03, 16:46 authored by Jorge Gómez-Miragaya, Sebastián Morán, Maria Eréndira Calleja-Cervantes, Alejandro Collado-Sole, Laia Paré, Antonio Gómez, Violeta Serra, Lacey E. Dobrolecki, Michael T. Lewis, Angel Diaz-Lagares, Pilar Eroles, Aleix Prat, Manel Esteller, Eva González-Suárez

DNA methylation signatures applied to breast cancer PDX models and comparasion with human normal mammary gland

Funding

AEI

Susan Komen Foundation

ERC

Instituto de Salud Carlos

Breast Cancer Research Foundation

NIH

NCI

BCM

ISCIII

History

ARTICLE ABSTRACT

Taxanes are standard therapy in clinical practice for metastatic breast cancer; however, primary or acquired chemoresistance are a common cause of mortality. Breast cancer patient-derived xenografts (PDX) are powerful tools for the study of cancer biology and drug treatment response. Specific DNA methylation patterns have been associated to different breast cancer subtypes but its association with chemoresistance remains unstudied. Aiming to elucidate docetaxel resistance mechanisms, we performed genome-wide DNA methylation in breast cancer PDX models, including luminal and triple-negative breast cancer (TNBC) models sensitive to docetaxel, their matched models after emergence of chemoresistance and residual disease after short-term docetaxel treatment. We found that DNA methylation profiles from breast cancer PDX models maintain the subtype-specific methylation patterns of clinical samples. Two main DNA methylation clusters were found in TNBC PDX and remain stable during the emergence of docetaxel resistance; however, some genes/pathways were differentially methylated according to docetaxel response. A DNA methylation signature of resistance able to segregate TNBC based on chemotherapy response was identified. Transcriptomic profiling of selected sensitive/resistant pairs and integrative analysis with methylation data demonstrated correlation between some differentially methylated and expressed genes in docetaxel-resistant TNBC PDX models. Multiple gene expression changes were found after the emergence of docetaxel resistance in TNBC. DNA methylation and transcriptional changes identified between docetaxel-sensitive and -resistant TNBC PDX models or residual disease may have predictive value for chemotherapy response in TNBC. Subtype-specific DNA methylation patterns are maintained in breast cancer PDX models. While no global methylation changes were found, we uncovered differentially DNA methylated and expressed genes/pathways associated with the emergence of docetaxel resistance in TNBC.

Usage metrics

    Molecular Cancer Research

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC